166 related articles for article (PubMed ID: 17415962)
1. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
2.
Sun B; Zhang Z; Dong C; Zhang Y; Yan C; Li S;
Eye (Lond); 2017 May; 31(5):668-676. PubMed ID: 28387769
[TBL] [Abstract][Full Text] [Related]
3. [The value of DCE-MRI in assessing the course of thyroid associated ophthalmopathy].
Wu T; Tang DR; Wang F; Xia S; Sun FY
Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):430-435. PubMed ID: 28606264
[No Abstract] [Full Text] [Related]
4. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
5. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease.
Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I
J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
[TBL] [Abstract][Full Text] [Related]
9. [The application of
Tang MT; Zeng XY; Li Y; Sun HT; Liu SY; Yuan X; Lu W
Zhonghua Yan Ke Za Zhi; 2021 Nov; 57(11):830-836. PubMed ID: 34743468
[No Abstract] [Full Text] [Related]
10. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
11. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
[TBL] [Abstract][Full Text] [Related]
12. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the ratio of orbital fat to total orbit area in mild-to-moderate thyroid-associated ophthalmopathy.
Kim HC; Yoon SW; Lew H
Br J Radiol; 2015 Sep; 88(1053):20150164. PubMed ID: 26151616
[TBL] [Abstract][Full Text] [Related]
14. [Nontarget area and threshold selection in 99mTc-DTPA orbital SPECT/CT imaging inthyroid associated ophthalmopathy].
Jiang C; Li X; Dend H; Liu J; Huang J; Liu D; Xu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 43(8):869-874. PubMed ID: 30197315
[TBL] [Abstract][Full Text] [Related]
15. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
[TBL] [Abstract][Full Text] [Related]
17. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
18. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of inflammatory activity in thyroid associated ophthalmopathy by SPECT/CT with 99mTc-DTPA].
Liu D; Xu X; Wen D; Tan J; Jiang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):457-460. PubMed ID: 29774886
[TBL] [Abstract][Full Text] [Related]
20. 111In-octreotide in the evaluation of autoimmune thyroid diseases.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Del Vecchio E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):127-30. PubMed ID: 9002770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]